1. Home
  2. ESQ vs DSGN Comparison

ESQ vs DSGN Comparison

Compare ESQ & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esquire Financial Holdings Inc.

ESQ

Esquire Financial Holdings Inc.

HOLD

Current Price

$123.60

Market Cap

941.0M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$11.84

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESQ
DSGN
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
941.0M
853.8M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
ESQ
DSGN
Price
$123.60
$11.84
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$120.33
$15.25
AVG Volume (30 Days)
118.9K
989.5K
Earning Date
04-23-2026
04-28-2026
Dividend Yield
0.76%
N/A
EPS Growth
14.20
N/A
EPS
1.40
N/A
Revenue
N/A
N/A
Revenue This Year
$35.15
N/A
Revenue Next Year
$39.09
N/A
P/E Ratio
$88.12
N/A
Revenue Growth
N/A
N/A
52 Week Low
$90.57
$3.76
52 Week High
$125.85
$17.25

Technical Indicators

Market Signals
Indicator
ESQ
DSGN
Relative Strength Index (RSI) 63.70 37.64
Support Level $103.79 $9.78
Resistance Level $124.95 $11.88
Average True Range (ATR) 3.50 1.09
MACD 0.22 -0.41
Stochastic Oscillator 75.10 0.74

Price Performance

Historical Comparison
ESQ
DSGN

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: